HomeCompareBTIIX vs ABBV

BTIIX vs ABBV: Dividend Comparison 2026

BTIIX yields 13.77% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $52.9K in total portfolio value· pulled ahead in Year 6
10 years
BTIIX
BTIIX
● Live price
13.77%
Share price
$156.49
Annual div
$21.55
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.4K
Annual income
$3,235.06
Full BTIIX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BTIIX vs ABBV

📍 ABBV pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBTIIXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BTIIX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BTIIX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BTIIX
Annual income on $10K today (after 15% tax)
$1,170.49/yr
After 10yr DRIP, annual income (after tax)
$2,749.80/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $18,306.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BTIIX + ABBV for your $10,000?

BTIIX: 50%ABBV: 50%
100% ABBV50/50100% BTIIX
Portfolio after 10yr
$75.9K
Annual income
$14,003.41/yr
Blended yield
18.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BTIIX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BTIIX buys
0
ABBV buys
0
No recent congressional trades found for BTIIX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBTIIXABBV
Forward yield13.77%3.06%
Annual dividend / share$21.55$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$49.4K$102.3K
Annual income after 10y$3,235.06$24,771.77
Total dividends collected$22.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BTIIX vs ABBV ($10,000, DRIP)

YearBTIIX PortfolioBTIIX Income/yrABBV PortfolioABBV Income/yrGap
1$12,077$1,377.05$11,550$430.00+$527.00BTIIX
2$14,477$1,554.27$13,472$627.96+$1.0KBTIIX
3$17,231$1,741.21$15,906$926.08+$1.3KBTIIX
4$20,374$1,936.93$19,071$1,382.55+$1.3KBTIIX
5$23,941$2,140.42$23,302$2,095.81+$639.00BTIIX
6← crossover$27,967$2,350.57$29,150$3,237.93$1.2KABBV
7$32,491$2,566.25$37,536$5,121.41$5.0KABBV
8$37,552$2,786.32$50,079$8,338.38$12.5KABBV
9$43,190$3,009.63$69,753$14,065.80$26.6KABBV
10$49,449$3,235.06$102,337$24,771.77$52.9KABBV

BTIIX vs ABBV: Complete Analysis 2026

BTIIXStock

Under normal circumstances, the adviser intends to invest at least 80% of assets, determined at the time of purchase, in stocks of companies included in the S&P 500® Index and in derivative instruments, such as futures contracts and options, that provide exposure to the stocks of companies in the index.

Full BTIIX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BTIIX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BTIIX vs SCHDBTIIX vs JEPIBTIIX vs OBTIIX vs KOBTIIX vs MAINBTIIX vs JNJBTIIX vs MRKBTIIX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.